1. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma, and Immunology. J Allergy Clin Immunol. 2006;117:S525–53.
2. Immune Deficiency Foundation website. Eight Guiding Principles for Safe, Effective, and Appropriate Use of IVIG. http://primaryimmune.org/wp-content/uploads/2011/11/Guiding-Principles-I.pdf . 2006. Date updated not stated. Accessed 31 Jan 2012.
3. Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res. 2007;38:122–32.
4. Gammagard Liquid (Immune Globulin Intravenous [Human] 10 %). Prescribing Information. Westlake Village, CA: Baxter Healthcare Corporation; 2011.
5. Bonilla FA, Geha RS. Intravenous immunoglobulin therapy. In: Austen KF, editor. Therapeutic Immunology. 2nd ed. Malden: Blackwell Science; 2001. p. 264–370.